Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights from the Literature

What We're Reading

Article Recommendations from Our Deputy and Senior Editors

DOI:  Published December 2017
  • Article
  • Info & Metrics
  • PDF
Loading

IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity


Embedded Image

Multiple checkpoints (from U.S. General Accounting Office via Flickr)

Checkpoint blockade has been a successful strategy in the unleashing of specific T-cell antitumor responses. The inhibitory receptor IL1R8 is highly expressed on human NK cells and increases during NK-cell maturation and activation. Through the use of IL1R8-deficient mice, IL1R8 was found to act as a checkpoint to NK cell–mediated antitumor and antiviral protection, suggesting that its blockade during therapy could enhance NK-cell activity.

Molgora M, …, Mantovani A. Nature 2017 Oct 25. doi:10.1038/nature24293.

HLA influence on tumor evasion and mutation


Embedded Image

MHC on DCs (from P Müller et al. Cancer Immunol Res 2014)

Which peptides are presented to T cells depends on available HLA alleles. Marty et al. found that find that recurrent tumor mutations generally contain poorly presented peptides, and if not well presented by a patient's HLA, then the probability increases that such mutations will appear in progressing tumors. McGranahan et al. developed a computational tool, LOHHLA, that uses sequencing data to measure the loss of HLA alleles in tumors. Allele loss was common in non–small cell lung cancer with high neoepitope loads and provided a mechanism for immune escape and outgrowth of mutated subclones.

Marty R, …, Carter H. Cell 2017 Oct 26. DOI: 10.1016/j.cell.2017.09.050.

McGranahan N, …, Swanton C. Cell 2017 Oct 26. DOI: 10.1016/j.cell.2017.10.001.

A nonimmune function of T cells in promoting lung tumor progression


Embedded Image

Amphiregulin (from the RCSB PDB)

Amphiregulin (Areg), a ligand for the epidermal growth factor receptor, was found to be produced by intratumoral regulatory and conventional CD4+ T cells. Areg was a positive factor in tumor growth, but a T cell–restricted deficiency of Areg did not impact antitumor immunity. Areg's effects were likely indirect, working through tumor-supportive stromal tissue.

Green JA, …, Rudensky AY. J Exp Med 2017 Oct 16. DOI: 10.1084/jem.20170356.

Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy


Embedded Image

Neutrophils (from Manuel et al. Cancer Immunol Res 2014)

c-MET primarily promotes oncogenesis when expressed on tumor cells, but inhibiting c-MET can also enhance antitumor immunity. This antitumor effect is due to inhibition of c-MET signaling in neutrophils, which prevents their recruitment to, and suppressive influence on, the tumor microenvironment, increasing the efficacy of adoptive T-cell and checkpoint immunotherapies.

Glodde N, …, Hölzel M. Immunity 2017 Oct 17;47:789–802.e9.

An interferon-independent lncRNA promotes viral replication by modulating cellular metabolism


Embedded Image

Long noncoding RNA (from Rfam Database via Wikimedia)

Viral infection can induce a long noncoding RNA (lncRNA-AC0D1) that, independent of type 1 interferons or the IRF3 pathway, enhances viral replication; eliminating it reduces viral titers. lncRNA-AC0D1 directly binds to GOT2, a key metabolic enzyme that mediates lncRNA-AC0D1 effects. Mutational and functional analyses revealed that lncRNA binding enhanced GOT2 catalytic activity. Intervening with this metabolic pathway in metabolically dysregulated settings such as tumor microenvironments may prove useful.

Wang P, …, Cao X. Science Oct 26. DOI: 10.1126/science.aao0409.

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial


Embedded Image

Unanticipated beneficial outcomes (from N. Potanin via Flickr)

A clinical trial with 10,000 atherosclerosis patients (CANTOS) measured the effects of canakinumab, an antibody to IL1β, on cardiac events and also tracked the frequency of subsequent tumors. Those developing lung cancer had higher baseline IL6 and C-reactive protein. Lung, unlike other cancers, arose significantly less frequently if patients received canakinumab, supporting this pathway's importance in lung cancer and highlighting it for potential targeting.

Ridker PM, …, Glynn RJ. Lancet 2017 Oct 21;390:1833–42.

  • ©2017 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Immunology Research: 5 (12)
December 2017
Volume 5, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
What We're Reading
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
What We're Reading
Cancer Immunol Res December 1 2017 (5) (12) 1057;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
What We're Reading
Cancer Immunol Res December 1 2017 (5) (12) 1057;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity
    • HLA influence on tumor evasion and mutation
    • A nonimmune function of T cells in promoting lung tumor progression
    • Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy
    • An interferon-independent lncRNA promotes viral replication by modulating cellular metabolism
    • Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • What We're Reading
  • What We're Reading
  • What We're Reading
Show more Highlights from the Literature
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement